The Food and Drug Administration (FDA) has approved a series of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib (Iressa®) and erlotinib (Tarceva®), which have remarkably increased the 5-year survival rate of cancer patients with relatively high levels of EGFR expression or some form of EGFR mutation [4–6]. Here, EGFR is linked to cancer.